Targeting c-kit receptor in neuroblastomas and colorectal cancers using stem cell factor (SCF)-based recombinant bacterial toxins
- 552 Downloads
Autocrine activation of c-kit (KIT receptor tyrosine kinase) has been postulated to be a potent oncogenic driver in small cell lung cancer, neuroblastoma (NB), and poorly differentiated colorectal carcinoma (CRC). Although targeted therapy involving tyrosine kinase inhibitors (TKIs) such as imatinib mesylate is highly effective for gastrointestinal stromal tumor carrying V560G c-kit mutation, it does not show much potential for targeting wild-type KIT (WT-KIT). Our study demonstrates the role of stem cell factor (SCF)-based toxin conjugates for targeting WT-KIT-overexpressing malignancies such as NBs and CRCs. We constructed SCF-based recombinant bacterial toxins by genetically fusing mutated form of natural ligand SCF to receptor binding deficient forms of Diphtheria toxin (DT) or Pseudomonas exotoxin A (ETA') and evaluated their efficacy in vitro. Efficient targeting was achieved in all receptor-positive neuroblastoma (IMR-32 and SHSY5Y) and colon cancer cell lines (COLO 320DM, HCT 116, and DLD-1) but not in receptor-negative breast carcinoma cell line (MCF-7) thereby proving specificity. While dose- and time-dependent cytotoxicity was observed in both neuroblastoma cell lines, COLO 320DM and HCT 116 cells, only an anti-proliferative effect was observed in DLD-1 cells. We prove that these novel targeting agents have promising potential as KIT receptor tyrosine kinase targeting system.
KeywordsProtein-fusion toxins Stem cell factor c-kit receptor Targeting
We are grateful to Aslam Basha for helping with fermentation, DAAD and MHRD for providing fellowships to SC, and the Department of Biotechnology (DBT), Government of India for providing grant (BT/PR13463/PID/06/488/2010) to support this work.
Conflict of interest
The authors declare that they have no competing interests.
This article does not contain any studies with human participants or animals performed by any of the authors.
- Bellone G, Silvestri S, Artusio E, Tibaudi D, Turletti A, Geuna M, Giachino C, Valente G, Emanuelli G, Rodeck U (1997) Growth stimulation of colorectal carcinoma cells via the c-kit receptor is inhibited by TGF-1. J Cell Physiol 172:1–11. doi: 10.1002/(SICI)1097-4652(199707)172:1<1::AID-JCP1>3.0.CO;2-S PubMedCrossRefGoogle Scholar
- Bellone G, Smirne C, Carbone A, Buffolino A, Scirelli T, Prati A, Solerio D, Pirisi M, Valente G, Nano M, Emanuelli G (2006) KIT/stem cell factor expression in premalignant and malignant lesions of the colon mucosa in relationship to disease progression and outcomes. Int J Oncol 29:851–859. doi: 10.3892/ijo.29.4.851 PubMedGoogle Scholar
- Bruell D, Stöcker M, Huhn M, Redding N, Kupper M, Schumacher P, Paetz A, Bruns CJ, Haisma HJ, Fischer R (2003) The recombinant anti-EGF receptor immunotoxin 425 (scFv)-ETA'suppresses growth of a highly metastatic pancreatic carcinoma cell line. Int J Oncol 23:1179–1186. doi: 10.3892/ijo.23.4.1179 PubMedGoogle Scholar
- Burnette WN (1981) "Western blotting": electrophoretic transfer of proteins from sodium dodecyl sulfate-polyacrylamide gels to unmodified nitrocellulose and radiographic detection with antibody and radioiodinated protein A. Anal Biochem 112:195–203. doi: 10.1016/0003-2697(81)90281-5 PubMedCrossRefGoogle Scholar
- Demetri GD, Von Mehren M, Blanke CD, Van Den Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M, Fletcher JA, Silverman SG, Silberman SL, Capdeville R, Kiese B, Peng B, Dimitri-jevic S, Druker BJ, Corless C, Fletcher CDM, Joensuu H (2002) Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347:472–480. doi: 10.1056/NEJMoa020461 PubMedCrossRefGoogle Scholar
- Ding R, Jiang X, Ha Y, Wang Z, Guo J, Jiang H, Zheng S, Shen Z, Jie W (2015) Activation of Notch1 signalling promotes multi-lineage differentiation of c-KitPOS/NKX2. 5POS bone marrow stem cells: implication in stem cell translational medicine. Stem Cell Res Ther 6:1–15. doi: 10.1186/s13287-015-0085-2 CrossRefGoogle Scholar
- Frankel AE, Woo JH, Ahn C, Pemmaraju N, Medeiros BC, Carraway HE, Frankfurt O, Forman SJ, Yang XA, Konopleva M, Garnache-Ottou F, Angelot-Delettre F, Brooks C, Szarek M, Rowinsky E (2014) Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients. Blood 124(3):385–392. doi: 10.1182/blood-2014-04-566737 PubMedPubMedCentralCrossRefGoogle Scholar
- Högenauer C, Langner C, Lipp RW, Höfler G, Krejs GJ, Hinterleitner TA (2003) Complete remission of a metastatic gastrointestinal stromal tumour with the tyrosine kinase inhibitor imatinib (STI 571): effect of low dosage in an advanced tumour with exon 11 mutation. Eur J Gastroenterol Hepatol 15:323–327. doi: 10.1097/00042737-200303000-00017 PubMedCrossRefGoogle Scholar
- Howlader N, Noone AM, Krapcho M, Garshell J, Neyman N, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds) (2013) SEER cancer statistics review, 1975–2010. National Cancer Institute Bethesda, MD. http://seer.cancer.gov/csr/1975_2010/. Accessed 5 June 2015
- Kreitman RJ, Stetler-Stevenson M, Margulies I, Noel P, FitzGerald DJP, Wilson WH, Pastan I (2009) Phase II trial of recombinant immunotoxin RFB4 (dsFv)-PE38 (BL22) in patients with hairy cell leukemia. J Clin Oncol 27:2983–2990. doi: 10.1200/JCO.2008.20.2630 PubMedPubMedCentralCrossRefGoogle Scholar
- Lebron MB, Brennan L, Damoci CB, Prewett MC, O’Mahony M, Duignan IJ, Credille KM, DeLigio JT, Starodubtseva M, Amatulli M, Zhang Y, Schwartz KD, Burtrum D, Balderes P, Persaud K, Surguladze D, Loizos N, Paz K, Kotanides H (2014) A human monoclonal antibody targeting the stem cell factor receptor (c-Kit) blocks tumor cell signaling and inhibits tumor growth. Cancer Biol Ther 15:1208–1218. doi: 10.4161/cbt.29523 PubMedPubMedCentralCrossRefGoogle Scholar
- Oganesyan N, Kim S-H, Kim R (2004) On-column chemical refolding of proteins. Pharmacogenomics 4:22–26Google Scholar
- Wels W, Beerli R, Hellmann P, Schmidt M, Marte BM, Kornilova ES, Hekele A, Mendelsohn J, Groner B, Hynes NE (1995) EGF receptor and p185erbB-2-specific single-chain antibody toxins differ in their cell-killing activity on tumor cells expressing both receptor proteins. Int J Cancer 60:137–144. doi: 10.1002/ijc.2910600120 PubMedCrossRefGoogle Scholar
- Zhang F, Shan L, Liu Y, Neville D, Woo J-H, Chen Y, Korotcov A, Lin S, Huang S, Sridhar R, Liang W, Wang PC (2013) An anti-PSMA bivalent immunotoxin exhibits specificity and efficacy for prostate cancer imaging and therapy. Adv Healthc Mater 2:736–744. doi: 10.1002/adhm.201200254 PubMedPubMedCentralCrossRefGoogle Scholar